International non- proprietary name: Cetuximab
Brand name: Erbitux
Target; Format: Erbitux EGFR; Chimeric IgG1
Indication first approved or reviewed: Colorectal cancer
First EU approval year: 2004
First US approved: 2004
International non- proprietary name: Cetuximab
Brand name: Erbitux
Target; Format: Erbitux EGFR; Chimeric IgG1
Indication first approved or reviewed: Colorectal cancer
First EU approval year: 2004
First US approved: 2004